Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOSNASDAQ:NARINYSE:STVNNASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$101.47+0.4%$94.76$77.10▼$163.71$5.80B0.8734,548 shs1.96 million shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.42 million shsN/ASTVNStevanato Group€24.66-1.7%€23.02€17.12▼€25.88€7.47B0.53339,247 shs544,500 shsTMDXTransMedics Group$131.45+1.1%$118.51$55.00▼$177.37$4.45B2.11.36 million shs623,091 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos0.00%+1.14%+7.57%+3.03%-14.26%NARIInari Medical0.00%0.00%0.00%0.00%+66.09%STVNStevanato Group0.00%+5.47%+11.84%+21.06%+34.46%TMDXTransMedics Group0.00%+6.39%+2.74%+95.38%-12.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.287 of 5 stars4.41.00.04.41.91.70.6NARIInari Medical0.4769 of 5 stars1.10.00.00.01.42.50.6STVNStevanato GroupN/AN/AN/AN/AN/AN/AN/AN/ATMDXTransMedics Group1.4046 of 5 stars1.42.00.00.01.62.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.75Moderate Buy$134.6732.71% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideSTVNStevanato Group 2.86Moderate BuyN/AN/ATMDXTransMedics Group 2.80Moderate Buy$127.33-3.13% DownsideCurrent Analyst Ratings BreakdownLatest TMDX, STVN, GKOS, and NARI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.006/17/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.005/9/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.005/1/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$176.00 ➝ $115.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$383.48M15.12N/AN/A$13.91 per share7.29NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91STVNStevanato Group€1.19B6.25€0.76 per share32.64€5.02 per share4.91TMDXTransMedics Group$441.54M10.07$1.65 per share79.89$6.81 per share19.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ASTVNStevanato Group€127.45M€0.5148.3542.522.3511.14%10.00%6.03%N/ATMDXTransMedics Group$35.46M$1.3696.6591.92N/A10.03%21.88%6.15%7/30/2025 (Estimated)Latest TMDX, STVN, GKOS, and NARI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/ALatest TMDX, STVN, GKOS, and NARI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.096.495.62NARIInari MedicalN/A1.771.40STVNStevanato Group0.221.831.26TMDXTransMedics Group1.929.108.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%NARIInari Medical90.98%STVNStevanato GroupN/ATMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipGKOSGlaukos6.40%NARIInari Medical10.60%STVNStevanato GroupN/ATMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.14 million53.48 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableSTVNStevanato Group5,521302.84 millionN/AOptionableTMDXTransMedics Group21033.82 million31.46 millionOptionableTMDX, STVN, GKOS, and NARI HeadlinesRecent News About These Companies2 Stocks That Have Doubled This Year and Are Still Worth Buying2 hours ago | fool.com28,870 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Lisanti Capital Growth LLCJune 29 at 6:33 AM | marketbeat.comPerigon Wealth Management LLC Purchases 4,543 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)June 29 at 4:07 AM | marketbeat.comTMDX - TransMedics Group Inc Sustainability - MorningstarJune 27 at 5:08 PM | morningstar.comMTransMedics Group Inc. (TMDX) Stock Price Today - WSJJune 26, 2025 | wsj.comReasons to Retain TransMedics Stock in Your Portfolio for NowJune 26, 2025 | zacks.comGlobal Assets Advisory LLC Invests $1.05 Million in TransMedics Group, Inc. (NASDAQ:TMDX)June 25, 2025 | marketbeat.comOppenheimer & Co. Inc. Has $5.25 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)June 25, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Solid Biosciences (SLDB) and Novo Nordisk (NVO)June 24, 2025 | theglobeandmail.comOppenheimer Raises TransMedics (TMDX) PT to $150 Following Key OrganOx Metra Label UpdateJune 24, 2025 | msn.comTransMedics' Turnaround: The Organ Transplant Leader Is Still A BuyJune 23, 2025 | seekingalpha.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Cornerstone Wealth Management LLCJune 21, 2025 | marketbeat.comBrokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $125.11June 20, 2025 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by SG Americas Securities LLCJune 19, 2025 | marketbeat.comBoasting A 18% Return On Equity, Is TransMedics Group, Inc. (NASDAQ:TMDX) A Top Quality Stock?June 18, 2025 | finance.yahoo.comTransMedics Group (NASDAQ:TMDX) Stock Price Down 4.9% - Should You Sell?June 18, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $150.00June 17, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Shareholders to ConnectJune 17, 2025 | accessnewswire.comATransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLCJune 17, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 17, 2025 | marketbeat.comHandelsbanken Fonder AB Sells 72,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)June 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May3 High-Growth Stocks Traders Love and Investors Should WatchBy Chris Markoch | June 5, 2025View 3 High-Growth Stocks Traders Love and Investors Should WatchTMDX, STVN, GKOS, and NARI Company DescriptionsGlaukos NYSE:GKOS$101.47 +0.41 (+0.41%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$101.58 +0.11 (+0.11%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Stevanato Group NYSE:STVN€24.66 -0.43 (-1.71%) As of 06/27/2025 03:58 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.TransMedics Group NASDAQ:TMDX$131.45 +1.39 (+1.07%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$132.44 +0.99 (+0.75%) As of 05:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
